LPs Allocating to Biotech
Biotech — therapeutics-focused investing covering preclinical, clinical, and commercial-stage drug development — is one of the most technically specialized private markets segments. Altss tracks the LP base across endowments, pharma corporate venture arms, specialist family offices, and sovereign wealth funds with observable biotech allocation.
Data provenance
Primary sources: SEC Form ADV, 13F filings, endowment Form 990s, pharma corporate-venture-arm disclosures, IPO lockup and BLA filing tracing, NIH grant recipient cross-referencing for academic-industrial networks, and proprietary Altss OSINT enrichment.
Stage (preclinical, clinical, commercial) and modality (biologics, small molecule, cell/gene therapy, mRNA, antibody-drug conjugate, AI drug discovery) tagged per LP. Biotech LP activity is tracked separately from broader healthcare (services, devices, diagnostics, healthtech).
By Altss Research Team · Reviewed quarterly.
State of biotech allocation
The biotech capital cycle has moved through three distinct phases since 2020: the 2021 peak when nearly every major LP allocated to biotech venture; the 2022–2024 reset when valuations compressed dramatically and LP appetite for new biotech commitments fell; and the 2025 recovery with renewed IPO activity and M&A from pharma.
AI-driven drug discovery has emerged as a distinct LP theme. Dedicated platforms combining machine learning with drug development attract a partially different LP base — overlapping with AI-fund LPs and traditional biotech specialists. See the AI-funds coverage for the adjacent allocator set.
How different LP types approach biotech
Endowments.
Historically the most sophisticated biotech LP cohort. Boston-adjacent endowments (Harvard, MIT, Johns Hopkins, UPenn) hold particularly deep biotech relationships alongside Stanford, UCSF, Duke, and Yale.
Family offices.
Specialist LPs — Waypoint Capital (Bertarelli), Broad Foundation-adjacent structures, biotech-founder offices from Moderna, Vertex, Alexion, and Genzyme exit cohorts, and tech-founder FOs with a life-sciences thesis.
Pharma corporate venture arms.
Substantial direct-investment presence; selectively act as LPs in biotech specialist funds. Lilly Ventures, Pfizer Ventures, Novartis Venture Fund, Bristol Myers Squibb, Amgen Ventures, GSK Ventures, Merck Global Health Innovation Fund, AbbVie, and Sanofi Ventures anchor the pharma-CVC cohort.
Sovereign wealth funds.
Growing biotech allocation — Temasek (via Seviora / ISP), GIC, Mubadala, and PIF/Sanabil have all increased biotech participation since 2020, typically via specialist-fund commitments or co-investment in commercial-stage transactions.
Notable LPs actively deploying into biotech
Representative allocators tracked in Altss with observable biotech LP or direct-investment activity.
- Family office: Waypoint Capital (Bertarelli); Broad Foundation–adjacent structures; biotech-founder offices post Moderna, Vertex, Alexion, and Genzyme; Gates Foundation MRI sleeve; Bayshore Global (Brin life-sciences exposure); Tao Capital.
- Endowments: Harvard Management Company, MIT IMCO, Johns Hopkins, Stanford, UCSF, UPenn, Duke, Yale Investments Office.
- Pharma CVCs: Lilly Ventures, Pfizer Ventures, Novartis Venture Fund, BMS venture, Amgen Ventures, GSK Ventures, Merck GHI, AbbVie CVC, Sanofi Ventures.
- Sovereign: Temasek / Seviora / ISP, GIC, Mubadala, PIF/Sanabil.
- Specialist VC-anchor LP pools: a16z Bio + Health, Flagship Pioneering principal structures, ARCH Venture Partners LP pools.
Recent signals
Biotech LP signals — biotech-specialist fund commitments, AI drug-discovery fund participation, cell and gene therapy commitments, pharma CVC LP activity, and new biotech-exit-driven FO formation — are surfaced inside the Altss platform on a rolling basis.
Public pages are a stable snapshot. Live feeds and verified decision-makers are available to authenticated users.
How to use this list for fundraising
Biotech fundraising requires scientific and clinical credibility at the GP level to a degree few other asset classes do.
01
Scientific credibility.
LPs weight scientific-advisory-board quality and GP team technical depth heavily. Named scientific advisors and clinical operator pedigree materially move LP conversion.
02
Modality fit.
Cell/gene-therapy LPs differ from small-molecule LPs; AI-driven-discovery LPs overlap only partially with traditional biotech LPs. Filter by modality, not just by 'biotech.'
03
Cycle timing.
Biotech LP appetite is cycle-dependent. Timing a raise to post-reset recovery matters more here than in most asset classes.
04
Pharma CVC signaling.
Documented LP or co-invest relationships with major pharma CVCs substantially improve broader LP conversion.
Frequently asked questions
How many LPs in Altss are actively allocating to biotech?
How has the 2022–2024 biotech reset affected LP behavior?
Are endowments still leading biotech allocators?
What is the role of AI drug discovery in current biotech fundraising?
How do sovereign wealth funds approach biotech?
Find the biotech LPs that match your modality and stage
Altss maps biotech allocators by modality, stage, and cycle posture — with verified decision-makers, pharma-CVC co-invest signals, and recent fund-commitment history.
